Abstracts tagged "Janus kinase (JAK) and patient-reported outcome measures"

Abstract Number: 551 • 2019 ACR/ARP Annual Meeting
Upadacitinib Treatment and the Routine Assessment of Patient Index Data 3 (RAPID3) Among Patients with Rheumatoid Arthritis
Martin Bergman¹, Yoshiya Tanaka ², Gustavo Citera ³, Sami Bahlas ⁴, Mira Ali ⁵, Sebastian Meerwein ⁶, Yanna Song ⁷ and Vibeke Strand ⁸, ¹Drexel University College of Medicine, Stockholm, Sweden, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁴Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ⁵AbbVie Inc., North Chicago, IL, USA, North Chiacgo, ⁶AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁷AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁸Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Upadacitinib (UPA) is an oral reversible JAK inhibitor engineered for greater selectivity for JAK1 vs JAK2, JAK3, and TYK2, and is currently being assessed…
Abstract Number: 1377 • 2019 ACR/ARP Annual Meeting
MTX Withdrawal in Patients with RA Who Achieve Low Disease Activity with Tofacitinib Modified-Release 11 Mg Once Daily + MTX: An Assessment of the Impact on the Short Form-36 Patient-Reported Outcome
Vibeke Strand¹, Janet Pope ², John Woolcott ³, Jose L. Rivas ⁴, Annette Diehl ³, Shixue Liu ⁵, David Gruben ⁶ and Stanley Cohen ⁷, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Western University, London, ON, Canada, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer SLU, Madrid, Spain, ⁵Pfizer Inc, Shanghai, China (People's Republic), ⁶Pfizer Inc, Groton, CT, ⁷Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib +/- background MTX has been shown to be an effective treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].